All Updates

All Updates

icon
Filter
Earnings/results
Elevation Oncology misses analyst consensus; net losses narrow for Q2 2023
Precision Medicine
Aug 3, 2023
This week:
Product updates
Burcon unveils canola protein isolate for egg replacement
Plant-based Dairy & Egg
Yesterday
Product updates
Bene Meat Technologies produces first cultivated burger at parity with premium beef
Cell-cultured Meat
Yesterday
Geographic expansion
Regulation/policy
The Better Meat Co. expands to Asia with Singapore approval for Rhiza mycoprotein
Plant-based Meat
Yesterday
Listing
Pony.ai files for US IPO
Auto Tech
Yesterday
Product updates
MineOS launches DSR management 2.0
Digital Privacy Tools
Yesterday
Product updates
LatticeFlow launches the first evaluation framework for EU AI Act compliance
Generative AI Infrastructure
Yesterday
Product updates
Cognitive3D launches custom dashboards for XR analytics
Extended Reality
Oct 16, 2024
Funding
Mindtech raises GBP 4.4 million in funding to develop AI vision technology
Extended Reality
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Identity & Access Management
Oct 16, 2024
Partnerships
Zscaler and Okta partner to enhance zero trust security initiatives
Next-gen Cybersecurity
Oct 16, 2024
Precision Medicine

Precision Medicine

Aug 3, 2023

Elevation Oncology misses analyst consensus; net losses narrow for Q2 2023

Earnings/results

  • Elevation Oncology reported a net loss per share of USD 0.37 in Q2 2023, missing analyst expectations by 15.6%. Net loss for the quarter decreased by 49.3% YoY to USD 10.1 million. Elevation Oncology is a clinical-stage company that does not generate any drug sales.

  • The company achieved a few milestones for the quarter, such as 1) highlighting first-in-human Phase I clinical data of SYSA1801 (EO-3021) and 2) completing public offering of common stock in June 2023, raising approximately USD 46.5 million in net proceeds.

  • Operating expenses for the quarter were USD 9.8 million (down 51.1% YoY). The decrease in operating expenses for Q2 2023 was mainly attributable to the reduction in R&D expenses (down 63.1% YoY), primarily due to the decrease in costs related to manufacturing clinical supply of seribantumab for use in the CRESTONE clinical trial. Further, administration costs for Q2 2023 was USD 3.8 million. 

  • Cash and cash equivalents stood at USD 107.9 million at the end of June 2023, increasing from USD 90.3 million in December 2022, which it claims is sufficient to operate until the second half of 2025.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.